Patients with hypertension and/or ischemic heart disease
Conditions
Interventions
Trade Name: Nebilet
Pharmaceutical Form: Tablet
Trade Name: Talliton
Pharmaceutical Form: Tablet
Trade Name: Betaloc Zok
Pharmaceutical Form: Tablet
Sponsors
Hungarian Kidney Foundation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - 18-70 yrs - patients with hypertension and/or ischemic heart disease to whom treatment with an oral beta-blocker is suggested Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - treatment with a beta-blocking agent within 3 months - being allergic to any of the components of the drugs - II-III degree AV-block - sick sinus syndrome - severe chronic obstructive pulmonary disease, asthma or bronchospasm - severe peripheral arterial disease - uncompensated heart failure - untreated pheochromocytoma - treatment with a MAO-inhibitor - pregnancy or lactation - severe liver damage or liver failure - psoriasis - severe hypertension (>180/110 mmHg) - atrial fibrillation - lack of informed consent - poor compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary aim of the present study is to determine how nebivolol, carvedilol and metoprolol affects central arterial pressure and aortic pulse wave velocity ;Secondary Objective: The secondary aim of the present study is to compare the efficacy of nebivolol, carvedilol and metoprolol in reducing central arterial pressure and aortic pulse wave velocity.;Primary end point(s): Primary end-points are changes in central arterial systolic pressure and aortic pulse wave velocity after 3 months of treatment. | — |
Countries
Hungary
Outcome results
None listed